Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERS Genetic Model in Neoadjuvant Chemotherapy for Breast Cancer
NCT03006614Phase 3Unknown
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine, cisplatin, gemcitabine and capecitabine in breast cancer (2 arms). Primary endpoint: Pathological Complete Response up to 96 months. Status: unknown.
02
Drugs
vinorelbinecisplatingemcitabinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03006614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006614.